Temozolomide in the management of dopamine agonist–resistant prolactinomas
- 23 April 2012
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 76 (6) , 877-886
Abstract
Background: The majority of prolactinomas respond to dopamine agonist therapy, but a proportion are resistant, requiring other treatments including surgery and/or radiotherapy. Temozolomide is an oral chemotherapy agent, which has been used as a salvage therapy to treat aggressive pituitary adenomas and carcinomas, including prolactinomas, unresponsive to all conventional treatment.Case Series: We report three patients where temozolomide was used in the treatment of refractory prolactinomas. Case 1 describes a patient with a highly invasive prolactinoma, resistant to all conventional therapy, which responded dramatically to temozolomide used as a salvage treatment. In case 2, temozolomide was used after incomplete surgical resection to relieve chiasmal compression and avoid chiasm exposure to radiotherapy. In case 3, temozolomide enabled radiotherapy to be deferred in a 16‐year old with a resistant prolactinoma. In all three cases, the tumours were negative by immunostaining for methylguanine methyltransferase (MGMT).Literature Review and Discussion: A review of the published literature reveals 51 reported cases of temozolomide treatment for pituitary tumours, including 20 prolactinomas. Fifteen of the 20 prolactinomas showed a good response to temozolomide. Our analysis demonstrates a strong association between MGMT‐negative staining and a good response to temozolomide (OR 9·35, P = 0·0030). Current clinical practice is to use temozolomide as a salvage therapy after all conventional modalities of treatment have failed. We suggest that, in selected cases, consideration should be given to using temozolomide earlier in the treatment algorithm.Keywords
This publication has 47 references indexed in Scilit:
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT statusEuropean Journal of Clinical Investigation, 2011
- Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2011
- Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six casesEuropean Journal of Endocrinology, 2010
- ProlactinomasNew England Journal of Medicine, 2010
- Gamma Knife Radiosurgery for Medically and Surgically Refractory ProlactinomasNeurosurgery, 2006
- Guidelines of the Pituitary Society for the diagnosis and management of prolactinomasClinical Endocrinology, 2006
- Advances in the Treatment of ProlactinomasEndocrine Reviews, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Transsphenoidal Microsurgical Therapy of Prolactinomas: Initial Outcomes and Long-term ResultsNeurosurgery, 1999
- Malignant Pituitary TumoursPituitary, 1998